Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in interstitial lung disorders.

L J Wesselius

    Comprehensive Therapy
    |May 1, 1984
    PubMed
    Summary

    Interstitial lung disorders involve inflammation that can lead to irreversible fibrosis. Treating inflammation with immunosuppressants may prevent fibrosis, but therapy is reserved for selected patients with potential benefit.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Nasal and pharyngeal eosinophil peroxidase levels in adults with poorly controlled asthma correlate with sputum eosinophilia.

    Allergy·2015
    Same author

    Increased lower respiratory tract iron concentrations in alkaloidal ("crack") cocaine users.

    Chest·2001
    Same author

    Influence of cigarette smoking on crocidolite-induced ferritin release by human alveolar macrophages.

    The Journal of laboratory and clinical medicine·2000
    Same author

    Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung.

    American journal of respiratory cell and molecular biology·2000
    Same author

    Increased concentrations of iron and isoferritins in the lower respiratory tract of patients with stable cystic fibrosis.

    American journal of respiratory and critical care medicine·1999
    Same author

    Effects of TNF-alpha and IL-1beta on iron metabolism by A549 cells and influence on cytotoxicity.

    The American journal of physiology·1999

    Area of Science:

    • Pulmonology
    • Immunology
    • Pathology

    Background:

    • Interstitial lung disorders present heterogeneously with similar clinical and physiological impacts.
    • These diseases feature a reversible inflammatory phase preceding irreversible pulmonary fibrosis.

    Purpose of the Study:

    • To explore the role of immunosuppressive therapy in managing interstitial lung disorders.
    • To identify patient subgroups who may benefit from immunosuppressive treatment.

    Main Methods:

    • Review of current understanding of interstitial lung disorders and treatment strategies.
    • Analysis of indications for immunosuppressive therapy based on potential therapeutic benefit and side effects.

    Main Results:

    • Treatment of the inflammatory component with immunosuppressants may prevent or reduce pulmonary fibrosis.
    • Avoiding known precipitating agents, like asbestos, is primary therapy.
    • Corticosteroids are beneficial in sarcoidosis, particularly for symptomatic or deteriorating patients.
    • Patients with high pulmonary inflammation (positive gallium scan, >28% lymphocytes on lavage) may benefit from corticosteroids.
    • A corticosteroid trial is reasonable for idiopathic pulmonary fibrosis patients due to its progressive nature.

    Conclusions:

    • Immunosuppressive therapy for interstitial lung disorders should be reserved for selected patients with likely therapeutic benefit.
    • Specific conditions like sarcoidosis and idiopathic pulmonary fibrosis have defined roles for corticosteroid treatment.

    Related Experiment Videos